Suppr超能文献

干性年龄相关性黄斑变性患者视觉功能的12个月纵向研究。

Longitudinal Study of Visual Function in Dry Age-Related Macular Degeneration at 12 Months.

作者信息

Hsu S Tammy, Thompson Atalie C, Stinnett Sandra S, Luhmann Ulrich F O, Vajzovic Lejla, Horne Anupama, Schuman Stefanie G, Toth Cynthia A, Cousins Scott W, Lad Eleonora M

机构信息

Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.

Roche Pharmaceutical Research and Early Development, Translational Medicine Neuroscience & Ophthalmology & Rare Diseases Biomarkers, Roche Innovation Center Basel, Basel, Switzerland.

出版信息

Ophthalmol Retina. 2019 Aug;3(8):637-648. doi: 10.1016/j.oret.2019.03.010. Epub 2019 Mar 21.

Abstract

PURPOSE

To report the 1-year progression of visual impairment on psychophysical tests of visual function in patients with early and intermediate age-related macular degeneration (AMD).

DESIGN

Prospective, observational study.

PARTICIPANTS

Patients with early and intermediate AMD were enrolled from the existing population at the Duke Eye Center, and healthy age-matched control participants were recruited from family members or friends of the AMD patients and from the Duke Optometry and Comprehensive Eye Clinics.

METHODS

Patients and control participants recruited during the baseline study were assessed at both 6 and 12 months after the initial study visit. Measurements of visual function included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), low-luminance deficit (LLD), microperimetry percent-reduced threshold (PRT), microperimetry average threshold (AT), and cone contrast tests (CCTs).

MAIN OUTCOME MEASURES

Changes in BCVA, LLVA, LLD, microperimetry PRT, microperimetry AT, and CCT results from baseline to 6 months and to 12 months were assessed.

RESULTS

Eighty-five patients completed the 12-month examination (19 control participants, 27 early AMD patients, and 39 intermediate AMD patients). Longitudinal analysis detected significant changes from baseline within each group in microperimetry PRT and AT and in the intermediate AMD group only for BCVA and CCT results (P < 0.05).

CONCLUSIONS

Microperimetry and CCT are able to detect functional changes resulting from progression of dry AMD within a period as short as 12 months. These functional markers may be useful end points in future clinical trials that assess the effect of potential treatments for AMD.

摘要

目的

报告早期和中期年龄相关性黄斑变性(AMD)患者视觉功能心理物理学测试中视力损害的1年进展情况。

设计

前瞻性观察性研究。

参与者

从杜克眼科中心的现有人口中招募早期和中期AMD患者,从AMD患者的家庭成员或朋友以及杜克验光和综合眼科诊所招募年龄匹配的健康对照参与者。

方法

在基线研究期间招募的患者和对照参与者在初次研究访视后的6个月和12个月时均进行评估。视觉功能测量包括最佳矫正视力(BCVA)、低亮度视力(LLVA)、低亮度缺陷(LLD)、微视野检查降低阈值百分比(PRT)、微视野检查平均阈值(AT)和视锥细胞对比测试(CCT)。

主要观察指标

评估从基线到6个月以及到12个月时BCVA、LLVA、LLD、微视野检查PRT、微视野检查AT和CCT结果的变化。

结果

85名患者完成了12个月的检查(19名对照参与者、27名早期AMD患者和39名中期AMD患者)。纵向分析发现,每组中微视野检查PRT和AT以及仅在中期AMD组中BCVA和CCT结果与基线相比有显著变化(P<0.05)。

结论

微视野检查和CCT能够在短短12个月内检测到干性AMD进展导致的功能变化。这些功能标志物可能是未来评估AMD潜在治疗效果的临床试验中有价值的终点指标。

相似文献

1
Longitudinal Study of Visual Function in Dry Age-Related Macular Degeneration at 12 Months.
Ophthalmol Retina. 2019 Aug;3(8):637-648. doi: 10.1016/j.oret.2019.03.010. Epub 2019 Mar 21.
2
Longitudinal Evaluation of Visual Function Impairments in Early and Intermediate Age-Related Macular Degeneration Patients.
Ophthalmol Sci. 2022 May 20;2(3):100173. doi: 10.1016/j.xops.2022.100173. eCollection 2022 Sep.
3
Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.
Am J Ophthalmol. 2018 May;189:127-138. doi: 10.1016/j.ajo.2018.02.012. Epub 2018 Mar 15.
4
Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration.
JAMA Ophthalmol. 2015 Apr;133(4):442-8. doi: 10.1001/jamaophthalmol.2014.5963.
5
Low-luminance visual acuity and microperimetry in age-related macular degeneration.
Ophthalmology. 2014 Aug;121(8):1612-9. doi: 10.1016/j.ophtha.2014.02.005. Epub 2014 Mar 22.
8
Microperimetry in age-related macular degeneration: association with macular morphology assessed by optical coherence tomography.
Br J Ophthalmol. 2019 Dec;103(12):1769-1776. doi: 10.1136/bjophthalmol-2018-313316. Epub 2019 Feb 1.
9
VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.
Retina. 2016 May;36(5):1021-31. doi: 10.1097/IAE.0000000000001002.
10
Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.
Ophthalmol Sci. 2021 Dec 22;2(1):100095. doi: 10.1016/j.xops.2021.100095. eCollection 2022 Mar.

引用本文的文献

2
Heterogeneous Visual Function Deficits in Intermediate Age-Related Macular Degeneration: A MACUSTAR Report.
Ophthalmol Sci. 2025 Jan 13;5(4):100708. doi: 10.1016/j.xops.2025.100708. eCollection 2025 Jul-Aug.
5
Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration.
Ophthalmol Ther. 2023 Dec;12(6):2917-2941. doi: 10.1007/s40123-023-00807-9. Epub 2023 Sep 29.
8
Comparing Rod-Mediated Dark Adaptation in Older Adults before and after Cataract Surgery.
Curr Eye Res. 2023 May;48(5):512-517. doi: 10.1080/02713683.2023.2171438. Epub 2023 Jan 30.
9
Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study.
Ophthalmol Sci. 2021 Dec 22;2(1):100095. doi: 10.1016/j.xops.2021.100095. eCollection 2022 Mar.
10
Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study.
Ophthalmol Sci. 2021 Nov 27;2(1):100086. doi: 10.1016/j.xops.2021.100086. eCollection 2022 Mar.

本文引用的文献

1
Visual Function Endpoints to Enable Dry AMD Clinical Trials.
Drug Discov Today Ther Strateg. 2013 Spring;10(1):e43-e50. doi: 10.1016/j.ddstr.2012.11.002. Epub 2013 Feb 28.
2
Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.
Am J Ophthalmol. 2018 May;189:127-138. doi: 10.1016/j.ajo.2018.02.012. Epub 2018 Mar 15.
3
Long-term longitudinal modifications in mesopic microperimetry in early and intermediate age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 2017 Feb;255(2):301-309. doi: 10.1007/s00417-016-3466-z. Epub 2016 Aug 31.
4
Adjust for Multiple Comparisons? It's Not That Simple.
Ann Thorac Surg. 2016 May;101(5):1644-5. doi: 10.1016/j.athoracsur.2015.11.024.
5
VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.
Retina. 2016 May;36(5):1021-31. doi: 10.1097/IAE.0000000000001002.
6
Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration.
JAMA Ophthalmol. 2015 Apr;133(4):442-8. doi: 10.1001/jamaophthalmol.2014.5963.
7
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3.
8
Low-luminance visual acuity and microperimetry in age-related macular degeneration.
Ophthalmology. 2014 Aug;121(8):1612-9. doi: 10.1016/j.ophtha.2014.02.005. Epub 2014 Mar 22.
9
Six persistent research misconceptions.
J Gen Intern Med. 2014 Jul;29(7):1060-4. doi: 10.1007/s11606-013-2755-z. Epub 2014 Jan 23.
10
Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography.
Ophthalmology. 2014 Jan;121(1):162-172. doi: 10.1016/j.ophtha.2013.07.013. Epub 2013 Aug 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验